HUE055732T2 - Új tetrazolvegyületek és felhasználásuk a tuberkulózis kezelésében - Google Patents

Új tetrazolvegyületek és felhasználásuk a tuberkulózis kezelésében

Info

Publication number
HUE055732T2
HUE055732T2 HUE18755815A HUE18755815A HUE055732T2 HU E055732 T2 HUE055732 T2 HU E055732T2 HU E18755815 A HUE18755815 A HU E18755815A HU E18755815 A HUE18755815 A HU E18755815A HU E055732 T2 HUE055732 T2 HU E055732T2
Authority
HU
Hungary
Prior art keywords
tuberculosis
treatment
tetrazole compounds
new tetrazole
new
Prior art date
Application number
HUE18755815A
Other languages
English (en)
Hungarian (hu)
Inventor
Carlos Alemparte-Gallardo
Lourdes Encinas
Provencio Jorge Esquivias
Original Assignee
Glaxosmithkline Intellectual Property Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Intellectual Property Dev filed Critical Glaxosmithkline Intellectual Property Dev
Publication of HUE055732T2 publication Critical patent/HUE055732T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/041,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/061,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HUE18755815A 2017-08-17 2018-08-16 Új tetrazolvegyületek és felhasználásuk a tuberkulózis kezelésében HUE055732T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17382574 2017-08-17

Publications (1)

Publication Number Publication Date
HUE055732T2 true HUE055732T2 (hu) 2021-12-28

Family

ID=59713960

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE18755815A HUE055732T2 (hu) 2017-08-17 2018-08-16 Új tetrazolvegyületek és felhasználásuk a tuberkulózis kezelésében

Country Status (19)

Country Link
US (1) US11072591B2 (https=)
EP (1) EP3668856B1 (https=)
JP (1) JP7410017B2 (https=)
KR (1) KR102661367B1 (https=)
CN (1) CN110997651B (https=)
AU (1) AU2018317812C1 (https=)
CA (1) CA3072854A1 (https=)
CY (1) CY1124577T1 (https=)
DK (1) DK3668856T3 (https=)
ES (1) ES2885573T3 (https=)
HR (1) HRP20211326T1 (https=)
HU (1) HUE055732T2 (https=)
LT (1) LT3668856T (https=)
PL (1) PL3668856T3 (https=)
PT (1) PT3668856T (https=)
RS (1) RS62267B1 (https=)
SI (1) SI3668856T1 (https=)
SM (1) SMT202100515T1 (https=)
WO (1) WO2019034729A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111184718A (zh) * 2018-11-15 2020-05-22 鲁南制药集团股份有限公司 法罗培南在制备治疗初治病原学阳性肺结核药物中的用途
CN115403533B (zh) * 2021-05-28 2023-08-25 永康市第一人民医院 一种1-苯乙烯基-1,2,3-三氮唑化合物及其制备方法和应用
CN116102483B (zh) * 2021-11-09 2025-01-17 中国医学科学院药物研究所 取代吡咯-2,5-二酮类化合物及其制备方法和用途
CN116726018A (zh) * 2023-08-02 2023-09-12 上海市肺科医院(上海市职业病防治院) 一种贝达喹啉、德拉马尼、氯法齐明和吡嗪酰胺的联用和应用
CN117379430A (zh) * 2023-10-11 2024-01-12 深圳市第三人民医院(深圳市肝病研究所) 一种地拉韦啶的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3621427B2 (ja) 1997-07-22 2005-02-16 塩野義製薬株式会社 糸球体障害治療または予防剤
KR20120003499A (ko) * 2007-04-05 2012-01-10 지멘스 메디컬 솔루션즈 유에스에이, 인크. 클릭 화학을 이용한 탄산탈수효소―ⅰⅹ에 대한 분자 영상화 프로브의 제조
WO2017066964A1 (en) 2015-10-22 2017-04-27 Merck Sharp & Dohme Corp. Oxazolidinone compounds and methods of use thereof as antibacterial agents

Also Published As

Publication number Publication date
EP3668856B1 (en) 2021-06-23
WO2019034729A1 (en) 2019-02-21
BR112020003247A2 (pt) 2020-08-18
JP2020531425A (ja) 2020-11-05
CA3072854A1 (en) 2019-02-21
ES2885573T3 (es) 2021-12-14
CN110997651A (zh) 2020-04-10
SMT202100515T1 (it) 2021-11-12
PL3668856T3 (pl) 2021-12-13
CY1124577T1 (el) 2022-07-22
RU2020110818A (ru) 2021-09-17
EP3668856A1 (en) 2020-06-24
US20200231555A1 (en) 2020-07-23
RS62267B1 (sr) 2021-09-30
US11072591B2 (en) 2021-07-27
KR20200041915A (ko) 2020-04-22
JP7410017B2 (ja) 2024-01-09
HRP20211326T1 (hr) 2021-11-26
CN110997651B (zh) 2023-01-03
PT3668856T (pt) 2021-09-15
AU2018317812B2 (en) 2021-04-15
DK3668856T3 (da) 2021-09-20
RU2020110818A3 (https=) 2021-10-11
AU2018317812A1 (en) 2020-02-20
AU2018317812C1 (en) 2021-08-26
KR102661367B1 (ko) 2024-04-29
SI3668856T1 (sl) 2021-11-30
LT3668856T (lt) 2021-09-27

Similar Documents

Publication Publication Date Title
FR25C1046I1 (fr) Combinaisons thérapeutiques d'un inhibiteur de btk et d'un inhibiteur de bcl-2
HUE054548T2 (hu) Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében
IL259441A (en) Materials and methods for treatment of titin-based myopathies and other titinopaties
HUE055755T2 (hu) Szulfonolkarmabidok és rokon vegyületeik valamint felhasználásuk
EP3532092A4 (en) IMMUNOGLOBULINS AND USES THEREOF
HUE040395T2 (hu) Ápolóeszköz és eljárás
HUE052468T2 (hu) Arginázgátlók és terápiás alkalmazásaik
HUE055635T2 (hu) Probiotikumok alkalmazása a pikkelysömör kezelésben és/vagy megelõzésében
HUE042709T2 (hu) Cukorbetegség és elhízás kezelésére alkalmazható dehidrobenzofurán vegyületek
HUE065152T2 (hu) Fluor-fenil-béta-hidroxietilaminok és alkalmazásuk hiperglikémia kezelésében
HUE053449T2 (hu) Kompozíciók, amelyek tartalmazzák lizinspecifikus demetiláz-1 inhibitorát, amelynek van pirimidingyûrûje és azok felhasználása rák kezelésében
HUE071358T2 (hu) Benzolszulfonamid vegyületek és terápiás szerként való alkalmazásuk
LT3411021T (lt) Sakubitrilo ir valsartano derinio naujas panaudojimas
HUE055732T2 (hu) Új tetrazolvegyületek és felhasználásuk a tuberkulózis kezelésében
HUE063120T2 (hu) LRRC33-inhibitorok és alkalmazásuk
DK3104838T3 (da) Terapeutiske nanopartikler omfattende et terapeutisk middel og fremgangsmåder til fremstilling og anvendelse deraf
HUE045025T2 (hu) Heterobiciklusos vegyületek és alkalmazásuk tuberkulózis kezelésére
SI3262028T1 (sl) N-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamidne in N-(-4hidroksi-4-metil-cikloheksil)-4-(2-piridil)-benzensulfonamidne spojine in njihova terapevtska uporaba
PL3229794T3 (pl) Kombinacja farmaceutyczna obejmująca ponesimod i jej zastosowanie w leczeniu stwardnienia rozsianego
GB201715194D0 (en) Compounds and their therapeutic use
PL3592355T3 (pl) Kx2-391/kx-01 do zastosowania w leczeniu rogowacenia słonecznego
SI3268374T1 (sl) KV1.3 inhibitorji in njihova medicinska uporaba
HUE063621T2 (hu) ß-interferon elleni ellenanyagok és alkalmazásuk
HUE062784T2 (hu) Indolinon vegyületek és alkalmazásuk fibrotikus betegségek kezelésében
GB201617064D0 (en) Compounds and their therapeutic use